AUCTORES
Globalize your Research
Review Article
*Corresponding Author: Maria Luz Gunturiz A., Public Health Research Division, National Institute of Health. Avenue Street 26 No 51-20 CAN, Bogotá, D.C., Colombia.
Citation: Maria Luz Gunturiz A. (2020) Main cardiovascular manifestations induced by coronaviruses: about the new virus 2019-CoV. Journal of Clinical Cardiology and Cardiovascular Interventions, 3(6): Doi: 10.31579/2641-0419/043
Copyright: © 2020 Maria Luz Gunturiz A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 20 March 2020 | Accepted: 01 April 2020 | Published: 06 April 2020
Keywords: Coronavirus, cardiovascular disease, respiratory infections, cardiovascular complications.
Chronic diseases are the cause of the highest mortality worldwide. Its prevalence is increasing, especially in middle- and low-income countries, in populations with a longer life expectancy that have adopted, among others, healthier lifestyles and diets. On the other hand, there are no therapeutic strategies focused exclusively on this population when they occur. respiratory virus epidemics such as coronaviruses.
This review presents evidence that shows the main cardiovascular manifestations associated with infection by respiratory viruses and especially by coronaviruses.
The epidemics of severe acute respiratory infections (IRAG) are a threat to global health, with significant morbidity and mortality rates, over the past two decades.
Coronaviruses are enveloped nonsegmented positive-sense RNA viruses that belong to the Coronaviridae family. and the order Nidovirales. It has been described that they are distributed broadly among humans, other mammals, and birds and that cause respiratory, enteric, hepatic, and neurologic diseases [1-3].
Six coronavirus species are known to cause human disease: four viruses (229E, OC43, NL63, and HKU1) are prevalent and typically cause common cold symptoms in immunocompetent individuals [4, 5]. The two other strains, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are zoonotic in origin and have been linked to sometimes fatal illness [5, 6].
SARS-CoV was the causal agent of the severe acute respiratory syndrome outbreaks in 2002 and 2003 in Guangdong Province, China [7-9] and MERS-CoV was the pathogen responsible for severe respiratory disease outbreaks in 2012 in the Middle East [10].
Coronavirus infections are generally mild, but two epidemics caused by coronavirus have been reported: SARS-CoV was the causal agent of the severe acute respiratory syndrome outbreaks in 2002 and 2003 in Guangdong Province, China [1, 7-9, 11] and the MERS-CoV that was the pathogen responsible for severe respiratory disease outbreaks in 2012 in the Middle East [10, 12] that caused more than 10,000 cases, with 10% mortality rates for SARS-CoV and 37% for MERS-CoV [1,13,14].
Given the high prevalence and wide distribution of coronaviruses, the large genetic diversity and frequent recombination of their genomes, and increasing human–animal interface activities, novel coronaviruses are likely to emerge periodically in humans owing to frequent cross-species infections and occasional spillover events [1,6,15].
In December 2019, some cases of pneumonia caused by a new coronavirus, called 2019-CoV or Wuhan coronavirus, were reported for the first time because it is this city where the first cases were detected [14].
In the last decade, in addition to epidemics caused by other respiratory viruses, three major epidemic outbreaks caused by coronaviruses have been described.
The first one, caused by the SARS-CoV that caused a severe respiratory syndrome known as SARS (Severe Acute Respiratory Syndrome) that appeared in 2002 in China, and affected more than 8,000 people in 30 countries and caused 700 deaths with a mortality rate of 10.6%) [7].
In 2012, the MERS-CoV that causes the Middle East respiratory syndrome, which is why it was called MERS (Middle East Respiratory Syndrome) with more than 2400 cases detected and more than 800 deaths in 26 countries, reaching a mortality of 35%, although the vast majority of reported cases originated in the Arabian Peninsula [10, 16,-18].
The recently described in Wuhan, known as 2019-CoV that has animal origin, has been transmitted to man, and from person to person, with more than 134.000 cases (on March 12, 2020) and an approximate mortality of 7%, since its appearance 3 months ago [1, 19-21].
Because of its importance, it is worth mentioning the Influenza A (H1N1) virus that has been classified as a public health problem for humans. Since the 2009 pandemic, H1N1 flu has caused approximately 284,500 deaths, directly from respiratory infections and indirectly from secondary cardiovascular diseases associated with bacterial infections [22-25].
Main symptoms and clinical manifestations in new coronavirus infection
All these viruses are directed to the respiratory tract and share many similar clinical symptoms, the most common being fever, cough, dyspnea, myalgia or fatigue, shortness of breath and sore throat always followed by gastrointestinal symptoms such as nausea, vomiting and diarrhea [22-26-28]. These respiratory diseases often present complications such as pneumonia, acute respiratory distress syndrome, organ failure and even death and mainly affect the respiratory system with organ failure, followed by the renal and cardiovascular systems [24, 25].
It is estimated that the infection has an incubation period of 2 to 14 days with potential for asymptomatic transmission, unlike the involvement of SARS. Due to clinical manifestations, it may be like other viral infections such as influenza and deceased patients have presented severe pulmonary diseases such as pneumonia with respiratory failure. However, other symptoms and complications related to infection with this coronavirus are still unknown, as well as the involvement of organs and tissues other than those of the respiratory system [1, 19-21].
The new coronavirus affects men, women, and children just as often. However, the consequences are very different, depending on age, sex and previous illnesses.
With the new coronavirus, the elderly is most at risk. The mortality rate increases exponentially from the age of 65, approximately. In China, for example, the mortality rate of infected people who are up to 40 years old is 0.2%, but among those who are 70 and 79 years old, it increases to 8%, while from the 80s years, increases to 14.8% [1, 19].
Instead, people between 21 years and 50 years are mainly infected with H1N1 with an average age of 40 years [23-25].
Involvement of coronaviruses with cardiovascular complications
To date, there are no studies that report the presence of cardiovascular complications caused by coronaviruses in general, nor by 2019-nCoV specifically. Huang et al [1] reported 12% of acute heart involvement in 41 patients with a confirmed diagnosis of Wuhan coronavirus infection, all hospitalized with pneumonia, one third of whom were admitted to the intensive care unit. Cardiac involvement was diagnosed if new electrocardiographic or echocardiographic abnormalities were present and all of them presented troponin elevation. All patients were treated with antibiotics, antivirals, corticosteroids and according to their evolution invasive mechanical ventilation.
Most of the available information on cardiac involvement due to coronavirus comes primarily from reports of isolated cases of other coronaviruses, Yu et al [29], published a study evaluating cardiovascular complications based on clinical and radiological detection in 121 cases of SARS, without systematically using the electrocardiogram, echocardiogram, Holter or other cardiovascular examinations, so there could be a underreporting of the cardiovascular condition [29-31].
According to all these reports, the main cardiovascular manifestations induced by coronaviruses, respiratory and syncytial viruses are persistent sinus tachycardia, myocarditis, hypotension, cardiac insufficiency, arrythmias, cardiogenic shock and acute infarct of the myocardium.
The table 1 summarizes the main symptoms and signs at the cardiovascular level as a result of virus infection.
Although SARS-CoV survivors benefited from clinical treatments that targeted the virus and inflammation, the recovered patients in the current study continued to experience a poor quality of life 12 years after their infections. Patients had experienced various diseases, including lung susceptibility to infections, tumors, cardiovascular disorders, and abnormal glucose metabolism. As compared to healthy controls, metabolomic analyses identified significant differences in the serum metabolomes of SARS survivors [37].
Respiratory virus (RV) infections have been implicated in acute exacerbation of cardiopulmonary conditions. Influenza and respiratory syncytial viruses (RSV) were diagnosed in 21% of elderly patients with underlying cardiac and/or pulmonary comorbidities hospitalized for acute cardiopulmonary exacerbations [34, 38-40].
Coronavirus infection of the Middle East respiratory syndrome (MERS-CoV) is associated with serious life-threatening diseases and reports a mortality rate of approximately 35%, particularly in patients with underlying comorbidities. A systematic analysis of 637 cases of MERS-CoV suggests that diabetes and hypertension are equally prevalent in approximately 50% of patients. Heart disease is present in 30% and obesity in 16% of cases. These conditions regulate the synthesis of proinflammatory cytokines and impair the host's innate and humoral immune systems. In conclusion, protection against MERS-CoV and other respiratory infections can be improved if public health vaccination strategies are adapted to target people with chronic disorders [18, 25].
In a recent study, it was observed that, compared with subjects without comorbidities, severe pandemic influenza occurred significantly more frequently in those individuals who were obese and in those who suffered from cardiovascular disease, hypertension and neuromuscular diseases. It has also been observed that chronic conditions that influence the severity of MERS-CoV such as diabetes, hypertension, obesity and cardiovascular disease / coronary artery disease, have similar effects on other respiratory diseases such as influenza and influenza A H1N1. In contrast, the prevalence of comorbidities such as immunodeficiency and HIV has been low in severe cases of MERS-CoV compared, for example, with their rates in severe cases of influenza A H1N1 [18, 25].
Pathologies related to the metabolic syndrome, such as diabetes, hypertension, CAD/ CVD and obesity, together with their predisposing conditions, can be etiologically implicated to the pathogenesis of MERS-CoV. It has been described that these disorders negatively regulate the key mediators of the host's innate immune response to pathogenesis. Specifically, diabetes, hyperglycemia and insulinopenia attenuate the synthesis of proinflammatory cytokines such as gamma interferon (IFN-γ) and interleukins (IL) to functionally affect the innate and humoral immune systems of the host. Chronic diseases share several common characteristics with infectious disorders and their complications, such as endothelial dysfunction, proinflammatory status and attenuation of the innate immune response [18, 25, 41-44]. Cytokine overload related to the change from Th1 to Th2 in severe viral infection when accompanied by cytokine synthesis that arises from metabolic diseases, can be detrimental to the endothelium and lead to a series of subsequent complications [18, 25, 42]. The potential role of altered innate immunity and the change in the Th1 response for microbicidal action of IFN-γ to Th2 (IL-4, -5, -10 and -13 anti-inflammatory) in relating metabolic diseases with severe viral presentation may also be supported by the high prevalence of allergy observed in fatal viral infections and eosinophilic responses in other infections [45, 46]. In addition, metabolic disorders impair macrophage and lymphocyte functions with a subsequent reduced immune response status, which can make individuals more susceptible to complications of infectious diseases. Additionally, glycosylated hemoglobin levels (HbA1c) ≥ 9% have been associated with a 60% increase in the risk of hospitalization and severity related to pneumonia [47, 48] with a variation in OR for severe MERS-CoV between 7.2 and 15.7 in diabetic subjects [26-28, 49, 50].
Diabetes is one of the known documented contributing host-related risk factors in both H1N1 and MERS-CoV severe cases and associated with RV infections in general and is frequent in individuals developing fatal disease complications [23, 24, 27, 28, 25, 51]. This data may suggest an etiological relationship between diabetes and acute viral respiratory infections, as its related conditions downregulate the innate and humoral immune systems by reducing the function of T cells and neutrophils. On the other hand, hyperglycemia impairs critical components of innate immunity in vitro, such as chemotaxis, phagocytosis, and the bactericidal activity of neutrophils and macrophages and lead to secondary infections [25, 52-54].
The direct influence of diabetes or other cardiovascular and metabolic diseases, on acute respiratory infections still needs more research to estimate the frequency in severe viral conditions and to clarify the etiologic role in disease severity [25, 54].
Main clinical features of patients infected with 2019-nCoV
Huang C et al reported that 41 patients admitted to the hospital in January were confirmed as positive for 2019-nCoV. These authors mentioned that most of the infected patients were men (30/41 [73%]); less than half had underlying diseases (13 [32%]), including diabetes (8 [20%]), hypertension (6 [15%]), and cardiovascular disease (6 [15%]). The median age was 49.0 years. Common symptoms at disease onset were fever (40/41 [98%]), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11/39 [28%]), headache (3/38 [8%]), hemoptysis (2/39 [5%]), and diarrhea (1/38 [3%]). Dyspnea developed in 22 (55%) of 40 patients (mean time from disease onset to dyspnea 8 · 0 days ). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), ARNaemia (six [15%]), acute heart damage (5 [12%]), and secondary infection (4 [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. [1].
On the other hand, Yang J et al carried out a meta-analysis study to assess the prevalence of comorbidities in the 2019-nCoV infection patients and the risk of underlying diseases in severe patients compared to non-severe patients [55].
They reported, "Eight studies were included in the meta-analysis, including 46248 infected patients. The result showed the most prevalent clinical symptom was fever (91 ± 3, 95% CI 86-97%), followed by cough (67 ± 7 , 95% CI 59-76%), fatigue (51 ± 0, 95% CI 34-68%) and dyspnea (30 ± 4, 95% CI 21-40%). The most prevalent comorbidity were hypertension (17 ± 7, 95% CI 14-22%) and diabetes (8 ± 6, 95% CI 6-11%), followed by cardiovascular diseases (5 ± 4, 95% CI 4-7%) and respiratory system disease (2 ± 0 , 95% CI 1-3%). Compared with the non-severe patient, the pooled odds ratio of hypertension, respiratory system disease, cardiovascular disease in severe patients were (OR 2.36, 95% CI: 1.46-3.83), (OR 2.46, 95% CI: 1.76-3.44) and (OR 3.42, 95% CI: 1.88-6.22) respectively " [55].
Use of Angiotensin-Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARBs) in Infection with 2019-nCoV
According to initial reports from China, and subsequent evidence that high blood pressure may be associated with an increased risk of mortality in hospitalized subjects infected with 2019-nCoV, hypotheses have been put forward suggesting possible adverse effects of ACEI or ARBs. It has been especially suggested that these commonly used drugs may increase both the risk of infection and the severity of SARS-CoV2 or 2019-nCoV [56, 57].
The concern of patients using these drugs and their treating doctors arises from the observation that, similar to the coronavirus that causes SARS, the 2019-nCoV virus binds to a specific enzyme called ACE2 to infect cells, and ACE2 levels increase after treatment with ACEI and ARB [56-58].
Speculation about the safety of ACEI or ARB treatment in relation to 2019-nCoV does not have a strong scientific basis or supporting evidence. In fact, there is evidence from animal studies that these drugs may be quite protective against serious lung complications in patients with 2019-nCoV infection, but to date there are no human data [56-60].
Other studies have suggested that ACE-1 inhibitors, such as enalapril and ramipril, and angiotensin receptor antagonists ARB, such as candesartan and valsartan, may be effective in preventing and treating the effects of the 2019-nCoV coronavirus [56].
Recently, three clinical trials using ACEI treatment have been recorded. The first one aims to know the clinical differences between patients with hypertension with and without ACEI treatment when they suffered with the 2019-nCoV infections in China. The second of them supports the use of the recombinant human angiotensin converting enzyme 2 (rhACE2) as a treatment for patients with COVID-19 and the third corresponds to a clinical study to evaluate the effects of ACEI/BRA on the infection of new pneumonia by coronavirus (2019-nCoV) [56].
But what are the 2019-nCoV mechanisms to infect cells?
As indicated above, coronaviruses are single-stranded RNA viruses, approximately 120 nanometers in diameter, made up of surface glycoproteins that allow coronaviruses to enter host cells. These glycoproteins also give it that characteristic corona structure of these viruses.
These glycoproteins have two subunits; S1 that binds to receptors on the cell surface; and S2, which fuses with the cell membrane. In the host, a transmembrane serine protease (TMPRSS2), promotes the entry of SARS-Cov into cells by two separate mechanisms. After the S1 subunit binds to the ACE-2 enzyme on the cell membrane surface, TMPRSS2 activates glycoproteins and cleaves ACE-2. Likewise, TMPRSS2 also acts on the S2 subunit causing an irreversible conformational change, activating it and facilitating the fusion of the virus to the cell membrane, with which the virus enters the cell [56, 57].
Both the SARS-CoV-1 and SARS-CoV-2 viruses (with an approximate structural identity of 80%), enter the host cells taking advantage of the action of the angiotensin-converting enzyme, ACE-2, which is expressed in the membranes of many cells in the body, including pulmonary alveolar epithelial cells.
Accordingly, reducing ACE-2 activity in cell membranes could theoretically reduce the ability of SARS-CoV-2 to penetrate cells. However, ACEI, such as enalapril and ramipril, used to treat hypertension and heart failure, do not inhibit ACE-2 [56-58].
It is well described that ACE inhibition increases the concentration of circulating angiotensin I, which could be converted to angiotensin [56].
The presence of a higher amount of angiotensin I, due to ACE-1 inhibition, could tend to up regulate ACE-2. Moreover, in experimental animals, ACE-1 inhibitors and ARBs increase cardiac ACE-2 activity and it is unclear whether such up regulation would be appropriate or not. Increased production of angiotensin from angiotensin II under the action of ACE-2, despite reduced production of angiotensin could lead to increased anti-inflammatory activity, partly mediated by inhibition of COX-2 synthesis, and some protection against lung damage caused by the virus. However, since ACE inhibitors lower angiotensin II concentrations, it is unlikely to be a large effect. Moreover, increased anti-inflammatory activity (by administration of an NSAID or corticosteroids), may not be advantageous and could be harmful in virus infections [56, 59].
So what to do with patients suffering from high blood pressure and chronic heart disease and COVID-19 infection?
It is relevant to mention that patients with severe hypertension or chronic heart failure can worsen rapidly if the drugs that act on the renin-angiotensin system are discontinued, so it is recommended that patients who are taking ACE-1 inhibitors or ARB continue taking their medications and following the instructions of the American College of Cardiology who have stated that "in the event that patients with cardiovascular disease are diagnosed with 2019-nCoV, individualized treatment decisions should be made according to hemodynamic status and clinical presentation of each patient". On the other hand, the Hypertension Council of the European Society of Cardiology has described that there is still insufficient evidence to support a harmful effect of ACE-1 inhibitors and ARBs in the context of the pandemic outbreak of 2019-nCoV; and it is not possible to indicate that the expected benefits are greater than the potential harm in infected patients, therefore it is not prudent to institute any pharmacological therapy based on an unproven hypothesis [56-60].
It is necessary to wait for the results of the clinical studies that are being carried out, in order to have scientific evidence that can suggest whether or not to use conventional ACE-1 or ARB inhibitors to treat 2019-nCoV.
At the cardiac level, pre-existing conditions such as ischemic heart disease, hypertension, diabetes mellitus, hyperlipidemia, obesity and cardiac arrhythmias, among others, increase the complications and prevalence of infections caused by viruses and there is still ignorance about the medium and long-term effects of these respiratory infections in patients with the aforementioned pathologies and about which other organs and tissues besides the lungs and upper respiratory tract are being colonized the new coronavirus 2019-nCoV .
To date, it is unknown if there are more than two circulating coronaviruses in the countries affected by this epidemic, making therapeutic strategies, including the development of vaccines, more difficult, making it necessary to strengthen prevention measures and to have available Rapid, precise and specific diagnostic tests that allow confirming cases in a very short time, avoiding massive contagion of the population.
Finally, it is important to mention that in times where dengue serotypes, H1N1 and other seasonal influences circulate, as well as other respiratory viruses, with symptoms similar to those of the new coronavirus, it may be possible that their detection is underestimated or masked by these diseases, therefore surveillance of this event must be intensified and patients with cardiovascular diseases monitored.
Data from the start of the pandemic allow to infer that indeed patients with diabetes, high blood pressure and cardiovascular disease have a very high risk of having serious complications if they become infected with the 2019-nCoV, so a very rigorous clinical follow-up must be done to prevent die from such complications.
The author wishes to acknowledge the financial support provided by the National Institute of Health of Colombia.
The following abbreviations are used in this manuscript
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
